Thabo Ishmael Lejone

Thabo Ishmael Lejone

Auto-generated profile, based on publicly available information

Thabo Ishmael Lejone

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in JAMA
Verified
Journal Article
Open access
PDF file
NLNiklaus D. Labhardt
Niklaus D. Labhardt
IRIsaac Ringera
Isaac Ringera
TLThabo I. Lejone
Thabo I. Lejone
Thomas KlimkaitThomas Klimkait
Thomas Klimkait
JMJosephine Muhairwe
Josephine Muhairwe
TGTracy R. Glass
Tracy R. Glass
With the 90-90-90 targets, the global strategy to end AIDS focuses on treatment as prevention and early initiation of antiretroviral therapy (ART).1 The 90-90-90 targets refer to 90% of people living with HIV being aware of their status, 90% of those receiving ART, and 90% of those achieving viral suppression.2

14 February 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
NFNathan Ford
Nathan Ford
EGElvin Geng
Elvin Geng
TETom Ellman
Tom Ellman
COCatherine Orrell
Catherine Orrell
PEPeter Ehrenkranz
Peter Ehrenkranz
HBHelen Bygrave
Helen Bygrave
Nathan Ford and co-authors discuss global priorities in the provision of HIV prevention and treatment services.

28 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TGTracy Renee Glass
Tracy Renee Glass
LMLipontso Motaboli
Lipontso Motaboli
BNBienvenu Nsakala
Bienvenu Nsakala
MLMalebanye Lerotholi
Malebanye Lerotholi
FVFiona Vanobberghen
Fiona Vanobberghen
NLNiklaus Daniel Labhardt
Niklaus Daniel Labhardt
For HIV-positive individuals on antiretroviral therapy (ART), the World Health Organization (WHO) recommends routine viral load (VL) monitoring. We report on the cascade of care in individuals with unsuppressed VL after introduction of routine VL monitoring in a district in Lesotho. In Butha-Buthe district 12 clinics (11 rural, 1 hospital) send samples for VL testing to the district laboratory. We included data from patients aged ≥15 years from Dec 1, 2015 to November 1, 2018. As per WHO guidelines VL <1000 copies/mL are considered suppressed, those ≥1000copies/mL unsuppressed. Patients with unsuppressed VL receive adherence counseling and follow-up VL within 8–12 weeks. Two consecutively unsuppressed VLs should trigger switch to second-line ART. For analysis of the VL monitoring cascade we defined care to be “according to guidelines” if patients with unsuppressed VL received a follow-up VL within <180 days and follow-up VL was either re-suppressed, or again unsuppressed and the individual was switched to second-line within 90 days. For 9,949 individuals 24,948 VL tests were available. The majority were female (73%), median age 41 years (interquartile range 33–52), and 58% seen at rural clinics. Overall, 25% (260/1028) of individuals were managed according to guidelines: 40% (410/1028) had a follow-up VL within 180 days of their initial unsuppressed VL and 25% (260/1028) of those either re-suppressed or switched to second-line within 90 days. Female patients were more likely to have a follow-up VL done, (p = 0.015). In rural clinics rates of two consecutively unsuppressed VLs were higher than in the hospital (64% vs. 44%, p<0.001), and rural clinics were less likely to switch these patients to second-line (35% vs. 66%, p<0001). Our data show that in a real-life setting availability of routine VL monitoring may not be exploited to its potential. A lack of timely follow-up after a first unsuppressed VL and reluctance to switch patients with confirmed virological failure, reduce the benefit of VL monitoring, i.e. in the rural clinics. Future studies will have to assess models of care which ensure that VL results are met with an action and make use of scalable innovative approaches.

1 July 2016 in Medicine
Verified
Journal Article
Open access
NLNiklaus D. Labhardt
Niklaus D. Labhardt
JBJoëlle Bader
Joëlle Bader
TLThabo Ishmael Lejone
Thabo Ishmael Lejone
IRIsaac Ringera
Isaac Ringera
MHMichael A. Hobbins
Michael A. Hobbins
Thomas KlimkaitThomas Klimkait
Thomas Klimkait
The World Health Organization (WHO) guidelines on antiretroviral therapy (ART) define treatment failure as 2 consecutive viral loads (VLs) ≥1000 copies/mL. There is, however, little evidence supporting 1000 copies as an optimal threshold to define treatment failure. Objective of this study was to assess the correlation of the WHO definition with the presence of drug-resistance mutations in patients who present with 2 consecutive unsuppressed VL in a resource-limited setting. In 10 nurse-led clinics in rural Lesotho children and adults on first-line ART for ≥6 months received a first routine VL. Those with plasma VL ≥80 copies/mL were enrolled in a prospective study, receiving enhanced adherence counseling (EAC) and a follow-up VL after 3 months. After a second unsuppressed VL genotypic resistance testing was performed. Viruses with major mutations against ≥2 drugs of the current regimen were classified as “resistant”. A total of 1563 adults and 191 children received a first routine VL. Of the 138 adults and 53 children with unsuppressed VL (≥80 copies/mL), 165 (116 adults; 49 children) had a follow-up VL after EAC; 108 (74 adults; 34 children) remained unsuppressed and resistance testing was successful. Ninety of them fulfilled the WHO definition of treatment failure (both VL ≥1000 copies/mL); for another 18 both VL were unsuppressed but with <1000 copies/mL. The positive predictive value (PPV) for the WHO failure definition was 81.1% (73/90) for the presence of resistant virus. Among the 18 with VL levels between 80 and 1000 copies/mL, thereby classified as “non-failures”, 17 (94.4%) harbored resistant viruses. Lowering the VL threshold from 1000 copies/mL to 80 copies/mL at both determinations had no negative influence on the PPV (83.3%; 90/108). The current WHO-definition misclassifies patients who harbor resistant virus at VL below 1000 c/mL as “nonfailing.” Lowering the threshold to VL ≥80 copies/mL identifies a significantly higher number of patients with treatment-resistant virus and should be considered.

14 April 2016 in BMC Public Health
Verified
Journal Article
Open access
PDF file
NLNiklaus Daniel Labhardt
Niklaus Daniel Labhardt
IRIsaac Ringera
Isaac Ringera
TLThabo Ishmael Lejone
Thabo Ishmael Lejone
PMPhofu Masethothi
Phofu Masethothi
TTT’sEpang Thaanyane
T’sEpang Thaanyane
TGTracy Renée Glass
Tracy Renée Glass
Achievement of the UNAIDS 90-90-90 targets in Sub-Sahara Africa is challenged by a weak care-cascade with poor linkage to care and retention in care. Community-based HIV testing and counselling (HTC) is widely used in African countries. However, rates of linkage to care and initiation of antiretroviral therapy (ART) in individuals who tested HIV-positive are often very low. A frequently cited reason for non-linkage to care is the time-consuming pre-ART assessment often requiring several clinic visits before ART-initiation. This two-armed open-label randomized controlled trial compares in individuals tested HIV-positive during community-based HTC the proposition of same-day community-based ART-initiation to the standard of care pre-ART assessment at the clinic. Home-based HTC campaigns will be conducted in catchment areas of six clinics in rural Lesotho. Households where at least one individual tested HIV positive will be randomized. In the standard of care group individuals receive post-test counselling and referral to the nearest clinic for pre-ART assessment and counselling. Once they have started ART the follow-up schedule foresees monthly clinic visits. Individuals randomized to the intervention group receive on the spot point-of-care pre-ART assessment and adherence counselling with the proposition to start ART that same day. Once they have started ART, follow-up clinic visits will be less frequent. First primary outcome is linkage to care (individual presents at the clinic at least once within 3 months after the HIV test). The second primary outcome is viral suppression 12 months after enrolment in the study. We plan to enrol a minimum of 260 households with 1:1 allocation and parallel assignment into both arms. This trial will show if in individuals tested HIV-positive during community-based HTC campaigns the proposition of same-day ART initiation in the community, combined with less frequent follow-up visits at the clinic could be a pragmatic approach to improve the care cascade in similar settings. NCT02692027 , registered February 21, 2016

21 October 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AAAlain Amstutz
Alain Amstutz
TLThabo Ishmael Lejone
Thabo Ishmael Lejone
LKLefu Khesa
Lefu Khesa
MKMathebe Kopo
Mathebe Kopo
MKMpho Kao
Mpho Kao
NLNiklaus Daniel Labhardt
Niklaus Daniel Labhardt
Background: Community-based antiretroviral therapy (ART) dispensing by lay workers is an important differentiated service delivery model in sub-Sahara Africa. However, patients new in care are generally excluded from such models. Home-based same-day ART initiation is becoming widespread practice, but linkage to the clinic is challenging. The pragmatic VIBRA (Village-Based Refill of ART) trial compared ART refill by existing lay village health workers (VHWs) versus clinic-based refill after home-based same-day ART initiation.Methods and findings: The VIBRA trial is a cluster-randomized open-label clinical superiority trial conducted in 249 rural villages in the catchment areas of 20 health facilities in 2 districts (Butha-Buthe and Mokhotlong) in Lesotho. In villages (clusters) randomized to the intervention arm, individuals found to be HIV-positive during a door-to-door HIV testing campaign were offered same-day ART initiation with the option of refill by VHWs. The trained VHWs dispensed drugs and scheduled clinic visits for viral load measurement at 6 and 12 months. In villages randomized to the control arm, participants were offered same-day ART initiation with clinic-based ART refill. The primary outcome was 12-month viral suppression. Secondary endpoints included linkage and 12-month engagement in care. Analyses were intention-to-treat. The trial was registered on ClinicalTrials.gov (NCT03630549). From 16 August 2018 until 28 May 2019, 118 individuals from 108 households in 57 clusters in the intervention arm, and 139 individuals from 130 households in 60 clusters in the control arm, were enrolled (150 [58%] female; median age 36 years [interquartile range 30–48]; 200 [78%] newly diagnosed). In the intervention arm, 48/118 (41%) opted for VHW refill. At 12 months, 46/118 (39%) participants in the intervention arm and 64/139 (46%) in the control arm achieved viral suppression (adjusted risk difference −0.07 [95% CI −0.20 to 0.06];p =0.256). Arms were similar in linkage (adjusted risk difference 0.03 [−0.10 to 0.16];p =0.630), but engagement in care was non-significantly lower in the intervention arm (adjusted risk difference −0.12 [−0.23 to 0.003];p =0.058). Seven and 0 deaths occurred in the intervention and control arm, respectively. Of the intervention participants who did not opt for drug refill from the VHW at enrollment, 41/70 (59%) mentioned trust or conflict issues as the primary reason. Study limitations include a rather small sample size, 9% missing viral load measurements in the primary endpoint window, the low uptake of the VHW refill option in the intervention arm, and substantial migration among the study population.Conclusions: The offer of village-based ART refill after same-day initiation led to similar outcomes as clinic-based refill. The intervention did not amplify the effect of home-based same-day ART initiation alone. The findings raise concerns about acceptance and safety of ART delivered by lay health workers after initiation in the community.Trial registration: Registered with Clinicaltrials.gov (NCT03630549).